Stay updated on CV301-Nivolumab Combo in Metastatic CRC Clinical Trial
Sign up to get notified when there's something new on the CV301-Nivolumab Combo in Metastatic CRC Clinical Trial page.

Latest updates to the CV301-Nivolumab Combo in Metastatic CRC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check22 days agoChange DetectedThe web page has been significantly updated to include extensive details about a clinical trial, including information on study design, eligibility criteria, and treatment protocols. Key entities such as the U.S. Food and Drug Administration (FDA) and the U.S. Agency for Healthcare Research and Quality (AHRQ) have been mentioned, enhancing the credibility and context of the study.SummaryDifference100%
- Check36 days agoChange DetectedThe web page has removed a significant service alert regarding planned maintenance that would affect service availability for over 24 hours, as well as various details about a clinical trial for metastatic colorectal cancer, including study design, eligibility criteria, and treatment protocols.SummaryDifference99%
- Check43 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.1%
- Check50 days agoChange DetectedThe web page now includes a service alert regarding planned maintenance starting July 25th, indicating that most services will be unavailable for over 24 hours beginning at 9 PM EDT.SummaryDifference0.7%
- Check57 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference0.8%
Stay in the know with updates to CV301-Nivolumab Combo in Metastatic CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CV301-Nivolumab Combo in Metastatic CRC Clinical Trial page.